As previously reported, the Trump Administration has released its "Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs." Many of the recommendations in the Blueprint were previously made in President Trump's fiscal year 2019 budget proposal, while numerous others are framed as open-ended questions rather than policies. While the near-term impacts on drug pricing based upon the contemplated policy changes are questionable, the wide-ranging reforms under consideration — if enacted — could significantly impact virtually every segment of the health care industry involved in the drug distribution system. The public has an opportunity to comment formally on the Blueprint through July 16, 2018.
Reed Smith has prepared a Client Alert that provides a summary and analysis of the Blueprint. Please click here to read more.
This article is presented for informational purposes only and is not intended to constitute legal advice.
